Zevaskyn (prademagene zamikeracel) for wound treatment in individuals with recessive dystrophic epidermolysis bullosa: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)
Zevaskyn (prademagene zamikeracel) for wound treatment in individuals with recessive dystrophic epidermolysis bullosa: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG). // Genetics in Medicine Open. – URL: https://www.sciencedirect.com/science/article/pii/S2949774426009180?dgcid=rss_sd_all
Zevaskyn (prademagene zamikeracel) for wound treatment in individuals with recessive dystrophic epidermolysis bullosa: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine Open. https://www.sciencedirect.com/science/article/pii/S2949774426009180?dgcid=rss_sd_all
“Zevaskyn (prademagene zamikeracel) for wound treatment in individuals with recessive dystrophic epidermolysis bullosa: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG).” Genetics in Medicine Open.
@article{article3642,
title = {Zevaskyn (prademagene zamikeracel) for wound treatment in individuals with recessive dystrophic epidermolysis bullosa: A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)},
journal = {Genetics in Medicine Open},
url = {https://www.sciencedirect.com/science/article/pii/S2949774426009180?dgcid=rss_sd_all}
}
ABSTRACT Generating bioengineered cartilage that recapitulates the depth-dependent phenotype, structure, and function of native articular cartilage remains a challenge. While cartilage is rich in aggrecan and type II collagen, proper...